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Tuberculosis (TB) remains a leading cause of death among HIV-infected adults, in part because of delayed diagnosis and there-
fore delayed initiation of treatment. Recently, the Gene-Xpert platform, a rapid, PCR-based diagnostic platform, has been vali-
dated for the diagnosis of TB with sputum.We have evaluated the Xpert MTB/RIF assay for the diagnosis ofMycobacterium tu-
berculosis bacteremia and investigated its impact on clinical outcomes. Consecutive HIV-infected adults with fever and cough
presenting to Queen Elizabeth Central Hospital, Blantyre, Malawi, were recruited and followed up for 2 months. At presenta-
tion, three sputum samples were examined by smear, culture, and Xpert MTB/RIF assay for the presence ofM. tuberculosis and
blood was drawn for PCR with Xpert, for mycobacterial culture (Myco/F Lytic), and for aerobic culture. One hundred four pa-
tients were recruited, and 44 (43%) were sputum culture positive forM. tuberculosis. Ten were Xpert blood positive, for a sensi-
tivity of 21% and a specificity of 100%. The 2-week mortality rate was significantly higher among patients who were Xpert blood
positive than among those who were negative (40% versus 3%; multivariate odds ratio [OR] for death if positive, 44; 95% confi-
dence interval [CI], 3 to 662). This effect persisted on assessment of the mortality rate at 2 months (40% versus 11%; OR, 5.6;
95% CI, 1.3 to 24.6). When screening uncomplicated patients presenting with a productive cough for pulmonary TB, Xpert
blood offers no diagnostic advantage over sputum testing. Despite this, Xpert blood positivity is highly predictive of early death
and this test rapidly identifies a group of patients in urgent need of initiation of treatment.
Tuberculosis (TB) remains a leading cause of morbidity andmortality inHIV-infected adults, yet it is frequently difficult to
diagnose, especially when the focus of infection is extrapulmo-
nary. Autopsy studies in sub-Saharan Africa have revealed a high
frequency of undiagnosed disseminated Mycobacterium tubercu-
losis infection in HIV-infected patients (1–3). Several studies have
also reported a high prevalence of M. tuberculosis bacteremia, a
form of disseminated TB (4–9). The clinical presentation of M.
tuberculosis bacteremia mimics other bloodstream infections
(BSIs), making it particularly difficult to identify and treat. There-
fore, diagnostic tests that allow the early identification of M. tu-
berculosis bacteremia are urgently needed.
In addition to the clinical importance ofM. tuberculosis bacte-
remia, several studies have established the potential of blood for
TB detection by both culture and nucleic acid amplification test
(NAAT) (10–14). Blood is an attractive sample type for TB diag-
nosis, especially for patients who are unable to expectorate or have
paucibacillary sputum loads. Blood could be especially useful for
HIV-infected patients, given their higher likelihood of sputum
culture-negative, disseminated, or extrapulmonary TB (10, 11).
Blood can be more reliably collected than sputum and does not
pose the same respiratory biohazard either at collection or on
processing within the laboratory environment.
Previous NAAT-basedM. tuberculosis bacteremia studies have
had mixed results, with sensitivities of TB detection in peripheral
blood of 2 to 55% (10–14). The Xpert MTB/RIF is a NAAT that
has recently been evaluated for the diagnosis of TB with sputum.
This platform provides highly sensitive and specific detection of
M. tuberculosis directly in untreated sputum in less than 2 h (15),
but the assay cartridges hold a volume of only 1 ml. To improve
the sensitivity of detection in blood, a lysis and centrifugation
protocol was developed to enable 20 ml of blood to be tested in a
single Xpert MTB/RIF assay, as reported in the accompanying
article (16). Proof-of-principle data obtained with blood spiked
with BCG suggested that this protocol could detectM. tuberculosis
in blood with limits of detection of95% at 10 CFU/ml and 33%
at 0.5 CFU/ml, which are in the range needed for detection of M.
tuberculosis bacteremia in patients with HIV infection.
In this study, we prospectively evaluated the role of the Xpert
MTB/RIF platform in the diagnosis ofM. tuberculosis bacteremia
in HIV-infected Malawian patients presenting to hospital with
high clinical suspicion of TB. We investigated the diagnostic util-
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ity of blood, directly compared the NAAT with standard myco-
bacterial blood culture (Myco/F Lytic) for the diagnosis of M.
tuberculosis bacteremia, and investigated M. tuberculosis bactere-
mia as a risk factor for early death.
MATERIALS AND METHODS
Study design and population. An observational cohort study was de-
signed to evaluate the Xpert MTB/RIF assay for the detection ofM. tuber-
culosis in whole blood of HIV-positive, symptomatic adults, aiming to
establish whether there is potential value in sampling blood to diagnose
TB.We recruited patientswithHIV infection, fever of greater than 38.5°C,
and cough for at least 1 week in a setting with a high prevalence of TBwho
were therefore highly like to have TB.
Setting.Malawi is a sub-Saharan African country with a high prevalence
of HIV (estimated at 17.4% in 2010) (17) and where the rate of death in the
first 2 months of TB treatment remains high (18, 19). Queen Elizabeth Cen-
tral Hospital (QECH) is a 1,000-bed teaching hospital in Blantyre, one of the
two largest cities inMalawi, serving a population of approximately 1 million
people. Currently, however, routine microbiological investigation of inpa-
tients for TB is limited to microscopy of a set of two sputum smears for
acid-fast bacilli.
Study procedures. Baseline demographic and clinical information
was collected. All patients underwent a standard evaluation including
HIV testing, CD4 cell counting, and blood culture with an aerobic bottle
(BacT/Alert; bioMérieux). An additional 20 ml of blood was collected in
acid-citrate-dextrose solution B (ACD-B) tubes for the Xpert MTB/RIF
assay, and a further 10ml was collected formycobacterial blood culture in
Myco/F Lytic bottles. Three sputum samples were obtained (spot, morn-
ing, spot), two for standard smear and mycobacterial culture and one for
Xpert MTB/RIF testing. Third-generation Xpert MTB/RIF cartridges
were used, which have European Union Conformité Européenne in vitro
diagnostic approval but which are not yet approved in the United States.
The treatment of patients diagnosed with TB was in accordance with
Malawi national guidelines (20). All patients were followed up by the
study team at 2, 4, and 8 weeks.
Case definitions. The following case definitions were used: first, bac-
teriologically confirmed TB indicated by (i) two or more positive sputum
smears (from three specimens), (ii) positive growth of M. tuberculosis in
one or more sputum (two specimens) or blood (one specimen) cultures,
or (iii) a positive sputum Xpert MTB/RIF result (one specimen); second,
treated unconfirmed TB, i.e., patients without bacteriologically con-
firmed TB treated on the basis of clinical or radiological suspicion; and
third, not TB, i.e., patients whowere culture andXpertMTB/RIF negative
and not treated for TB.
Laboratory methods. All aerobic blood culture isolates were identi-
fied by standard diagnostic techniques (21).Organisms routinely found as
part of the normal skin or oral flora were considered to be contaminants,
including coagulase-negative staphylococci, diphtheroids, Bacillus spe-
cies, and alpha-hemolytic streptococci other than Streptococcus pneu-
moniae (after clinical consideration of endocarditis). Antibiotic suscepti-
bility testing was performed by the disc diffusion method according to
British Society of Antimicrobial Chemotherapy standards (22).
Smearsmade fromboth direct and concentrated sputum sampleswere
examined by iLED fluorescence microscopy (auramine O), with any pos-
itive results confirmed by Ziehl-Neelsen (ZN) staining. Sputum samples
used for mycobacterial culture were decontaminated with 3% NaOH for
15 min and concentrated by centrifugation before inoculation of the re-
suspended pellet into mycobacterial growth indicator tubes and Lowen-
stein-Jensen (LJ) medium for up to 6 and 8 weeks, respectively. Mycobac-
terial isolates were further verified as M. tuberculosis or nontuberculous
mycobacteria by microscopic cording and MPT-64 lateral-flow assays
(Capilia; TAUNS Laboratories, Inc., Numazu, Japan) or, if either test was
negative, growth on p-nitrobenzoic acid at room temperature and 45°C
(23). The third sputum specimen was processed for the Xpert MTB/RIF
assay in accordance with the manufacturer’s recommended protocol
(Cepheid, Sunnyvale, CA).
For mycobacterial blood culture, venous blood (5 ml) was inoculated
into 50ml broth (BactecMyco/F Lytic; BDMicrobiology Systems, Sparks,
MD) and incubated at 37°C. Bottles were inspected daily for the first 14
days and then once every 2 days with a handheld UVWoods lamp. Con-
tents of bottleswere concentrated by centrifugation (3,000 g for 20min)
either within 48 h after the first detection of fluorescence or at the end of
6 weeks of incubation (whichever occurred first). The concentrate was
examined by ZN and Gram staining to exclude bacterial contaminants
and subcultured on LJ medium. ZN stain-positive subcultures were then
verified by lateral-flow assay as described above.
Xpert MTB/RIF blood assay procedure. The protocol described in
the accompanying report was followed (16). In brief, of the 20ml of blood
drawn into four ACD-B tubes and inverted in accordance with the man-
ufacturer’s instructions, 18mlwas pooled, added to a centrifuge tubewith
lysis buffer, inverted, and centrifuged at 4,000 rpm (3,000 g) for 20min.
After the supernatant was discarded, the pellet was resuspended in 1ml of
phosphate-buffered saline (pH7.2) towhich 1ml of XpertMTB/RIF assay
sample reagent (SR) was added, incubated at room temperature for 15
min, and loaded into the sample chambers of Xpert MTB/RIF assay car-
tridges. The remaining 2-ml aliquot of blood was stored. At the end of the
study, positive blood samples and an equal number of negative samples
were retested with the Xpert MTB/RIF assay by using 1 ml of blood and
adding 1 ml of Xpert MTB/RIF SR to it in order to assess whether the
machine was as sensitive with smaller amounts of blood. The laboratory
technician was blinded to the samples to reduce bias.
Data management and statistical analyses.Data were collected onto
standardized proformas and entered into a secure Microsoft Access data-
base with an optical character recognition system (ORC; Cardiff Tele-
forms, Cardiff, United Kingdom). Comparisons between patient charac-
teristics were done by analysis of variance (ANOVA) or the Kruskal-
Wallis test for continuous parametric and nonparametric variables,
respectively. Categorical variables were assessed by the chi-square (2)
test. Analysis of risk factors for death was done by multivariate logistic
regression, and results were expressed as odds ratios (OR) with 95% con-
fidence intervals (CIs). Survival of different patient groups over 2 months
of follow-up was depicted by a Kaplan-Meier survival plot. Multivariate
analysis was performed on factors found to be significant by univariate
analysis by logistic regression. Statistical analysis used STATA v12 (Stata
Corporation, College Station, TX).
Ethics. Approval of this study was obtained from the University of
Malawi College of Medicine Research Ethics Committee (COMREC
number P.02/11/1030). Informed written consent was obtained prior to
enrollment in the study.
RESULTS
Characteristics of cohort. From August 2011 to November 2011,
104HIV-infected adult patientsmeeting the inclusion criteria (fe-
ver and cough) were recruited (Fig. 1). Only 84 (81%)were able to
produce a sputum sample before death or discharge, whereas all of
the patients had blood drawn.
Fourteen (13%) participants had died by the end of 2 months
of follow-up. Baseline characteristics are shown by vital status at 2
months in Table 1. The mean age was 37 years, and 68 (67%)
participants were male. Patients reported a median duration of
illness of 4 weeks. The mean hemoglobin level was 9.2 g/dl (n 
99), and the median CD4 cell count was 94/l (n  89, as there
were 15 assay failures). Nineteen patients had a positive blood
culture. M. tuberculosis was the most common isolate (n  9),
followed by S. pneumoniae (n  6), nontyphoidal Salmonella
(NTS; n  3), and Haemophilus influenzae type b (n  2). One
patient was coinfected with both M. tuberculosis and Salmonella
enterica serovar Typhimurium (Table 1). Univariate risk factors
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for death included male gender (P  0.02) and M. tuberculosis
bacteremia (P 0.016).
Eighty-two patients submitted three sputum samples, and a
further two submitted two sputum samples. Forty-four patients
(43%) met case definitions for bacteriologically confirmed TB,
and all of them were sputum culture positive. There were no ad-
ditional diagnoses of TB made by the Xpert MTB/RIF sputum
assay or by mycobacterial blood culture in sputum culture-nega-
tive patients. No mycobacteria other than M. tuberculosis were
isolated, and all samples positive by Xpert MTB/RIF assay (n 
33) were rifampin susceptible. Except for three invalid GeneXpert
tests (4%) reported for sputum samples, no errors or sputum
contamination events were observed.
All 104 patients were reviewed 2 weeks after discharge, and 95
were followed up until death or discharge from the study at 2
months. Follow-up visits ensured that patients had received the
results of their investigations and had commenced antiretroviral
therapywhere indicated byMalawian national guidelines. In total,
7/104 (7%) had died after 2 weeks, 14/95 (15%) had died at 2
months, and 9/104 (9%) were lost to follow-up.
Xpert-MTB/RIF assay for the diagnosis of TB fromblood.M.
tuberculosis was detected by Xpert MTB/RIF assay in 10/104 sam-
ples (10%),with 66 (63%)negative and 28 (27%) invalid results or
errors. Its sensitivity was 21% compared to that of the gold stan-
dard.Nine of these 10 patients were sputumculture positive; how-
ever, the 10th patient died before he could submit sputum; there-
fore, this patient was excluded from the sensitivity analysis. In
contrast, only 4/9 (44%) Xpert blood-positive cases were sputum
smear positive. The specificity of the Xpert blood assay was there-
fore 100% (95% CI, 94 to 100) (Table 2).
Although the sensitivity of 21% was identical to that of myco-
bacterial blood culture, there were some discrepancies between
blood culture and theNAAT; 4/9 patients found to be Xpert blood
positive were blood culture negative, while 4/9 patients who were
blood culture positive were Xpert M. tuberculosis negative. Five
patients were positive by both assays (56% concordance). The
mean time to culture positivitywas slightly less at 29 days forXpert
MTB/RIF-positive patients versus 34 days for Xpert MTB/RIF-
negative patients.
On retesting of anticoagulated blood from participants who
were Xpert blood assay positive, only 3/6 (50%) 1-ml aliquots
were found to be positive, supporting the use of a lysis-centrifu-
gation step to enable larger volumes of blood to be assayed by the
Xpert platform (16).
Characteristics of and clinical outcomes of M. tuberculosis
bacteremia. Of the 10 patients who were Xpert blood assay posi-
FIG 1 Flow chart of enrollment and exclusion criteria, study procedures, and survival analysis groups by Xpert MTB/RIF blood assay result. CFR, case fatality
rate.
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tive, 9 (90%) were male. Their mean hemoglobin level was signif-
icantly lower than that of the rest of the cohort at 6.5 g/dl (P 
0.0012), while their median CD4 cell count of 54/l showed a
trend toward being lower (P 0.09). The 10 patients did not show
a significant difference from the rest of the cohort at presentation
in terms of age or duration of illness (Table 3).
The most striking association between Xpert blood results and
clinical data related to patient outcome; 4/10 (40%) Xpert blood-
positive participants died in the first 2 weeks (Fig. 2), with an
adjustedORof death of 44 (95%CI, 3 to 662) (Table 4). This effect
persisted at 2 months, although the size of the effect was dimin-
ished (OR, 5.6; 85% CI, 1.3 to 24.6). Conversely, Xpert blood
assay-negative participants with confirmed TB had a remarkably
lowmortality rate at 2 weeks (0/35 died) and 2months (2/35 [6%]
died). Of the four patients who were Xpert blood assay positive
anddied, threewere positive by conventionalmycobacterial blood
culture; therefore, this effect was seen among TB blood culture-
positive patients too; theORof deathwith a positive blood culture
was 11.4 (1.8 to 70.0) at 2 weeks and 6.8 (1.5 to 31.6) at 2 months.
DISCUSSION
The main findings of this evaluation of the Xpert-MTB/RIF assay
with blood samples from febrile HIV-infected patients suspected
of having TB were that detection ofM. tuberculosis bacteremia by
NAAT was rapid and had high specificity (100%) but low sensi-
tivity (21%) compared to sputum culture. Xpert-MTB/RIF blood
results were highly predictive of early death, with 40% of the pos-
itive participants dyingwithin the first 2weeks of admission, com-
pared to none of 35 participants with confirmed TB who were
Xpert blood assay negative. The goodprognosis of theXpert blood
TABLE 1 Baseline characteristics according to vital status at 2 monthsa
Baseline characteristic Alive Dead P value
No. (%) of patients 90 (87) 14 (13)
No. (%) of males 56 (62) 13 (93) 0.02
Age (yr) 37.1 (10.6) 35.7 (7.9) 0.63
Avg duration (weeks) of illness (quartiles
25–75)
4 (2–4) 4 (3–8) 0.73
No. (%) with hemoptysis 17 (19) 1 (7) 0.28
No. (%) with night sweats 59 (66) 7 (50) 0.79
No. (%) with wt loss 78 (87) 13 (93) 0.46
Avg systolic blood pressure (mmHg) (SD) 117 (57) 107 (17) 0.52
Avg respiratory rate (28/min) (SD) 36 (42) 7 (50) 0.59
Avg Karnofsky score (quartiles 25–75) 70 (60–80) 70 (60–80) 0.79
No. (%) with hemoglobin level (g/dl) of:
7 13 (62) 7 (33) 0.03b
7–10 30 (80) 3 (8)
10.1–13 29 (91) 2 (6)
13.0 8 (80) 0 (0)
No. (%) with CD4 cell count/l of:
50 18 (72) 4 (16) 0.26b
50–200 32 (84) 3 (8)
200 22 (81) 3 (11)
Unknown 10 (71) 4 (29)
No. (%) with BSI due to:
Any pathogen 13 (72) 5 (28) 0.93
M. tuberculosis 5 (56) 4 (44) 0.016
Other 8 (89) 1 (11) 0.23
H. influenzae type b 1 (100) 0 (0)
NTS 2 (67) 1 (33)
S. pneumoniae 5 (100) 0 (0)
a Two bacteremic patients were lost to follow-up by 2 months: 1 with H. influenzae type b, 1 with S. pneumoniae.
b P value for trend.
TABLE 2 Sensitivities and specificities of both the Xpert MTB/RIF platform with blood and conventional mycobacterial blood culture against the
gold standard of sputum culture for TB diagnosisa
Test
No. positive/total, %
sensitivity (95% CI)
No. positive/total, %
specificity (95% CI)
No. positive/total, %
PPVb (95% CI)
No. positive/total, %
NPVc (95% CI)
Xpert MTB/RIF with blood 9/43, 21 (10–36) 61/61, 100 (94–100) 9/9, 100 (66–100) 60/94, 64 (53–74)
Blood culture 9/43, 21 (10–36) 61/61, 100 (94–100) 9/9, 100 (66–100) 60/94, 64 (54–74)
a The prevalence of TB in this study was 41%.
b PPV, positive predictive value.
c NPV, negative predictive value.
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assay-negative TB patients persisted to 2 months (2/35 [6%]
died), despite a high prevalence of risk factors for death such as
advanced immunosuppression, anemia, and WHO-defined clin-
ical “danger signs.” Blood was tested with the Xpert-MTB/RIF
assay only once, at presentation, because of the volume required;
however, there was no evidence of occultM. tuberculosis bactere-
mia in the follow-up of this cohort and therefore no rationale for
serial blood testing forM. tuberculosis.
In this study, the speedwithwhich patientswithM. tuberculosis
bacteremia died was striking (Fig. 2). Unlike our study patients,
people presenting to health care facilities in sub-Saharan Africa
are often too sick or simply unable to produce sputum, making
blood an attractive alternative sample for the diagnosis of TB.
Furthermore, diagnostic facilities for febrile patients are fre-
quently unavailable in sub-Saharan Africa; therefore, it is often
normal to exclude or treat malaria first and then empirically treat
bacterial infection and only after there is a failure to recover on
antibiotics to empirically treat TB. Our data suggest that patients
withM. tuberculosis bacteremia have a high risk of early death and
that this incremental approach to empirical therapy introduces a
potentially fatal delay in the initiation of anti-TB chemotherapy
(ATC). Rapid testing of blood for TBwith the Xpert platformmay
facilitate the rapid diagnosis of TB and consequently the early
initiation of ATC.
The Xpert MTB/RIF blood test identified 100% of the patients
who died of TB at 2 weeks and 67% (4/6) of those who died of TB
at 2 months and so could potentially be used to distinguish pa-
tients requiring more intensive investigation and therapy from
thosewhohave a goodprognosis under the current standardman-
agement approach. Of note, in the case of one of the two patients
with pulmonary TB withoutM. tuberculosis bacteremia who died,
the Xpert assay was not negative but failed. Also notable is thatM.
tuberculosis bacteremia accounted for a significant proportion of
the deaths of febrile HIV-infected adults in this setting, irrespec-
tive of the final diagnosis (population-attributable fraction, 28%
at 2 months postadmission).
Facilities were not available to induce sputum or perform
bronchoalveolar lavage for patients who were unable to produce
sputum or to perform postmortem examinations of all those who
died before they could produce a sample. This was the first field
test of the lysis-centrifugation protocol, which enables the con-
centration of large volumes of blood, and there were a number of
“pressure-abort” failures caused by high pressures within the test
cartridges, usually across the sample filter that is integrated into
the cartridge. Visible clots were noted in many of the blood sam-
ples drawn. This was not noted in blood samples drawn from
healthy volunteers in the U.S.-based study. Clots would logically
be an obvious cause of high pressures. The clots in the blood
suggest either an error in the technique used to draw blood or
something more fundamentally different such as clotting factor
activation associated with elevated cytokine levels because of sys-
temic illness or dehydration. Further investigation is needed, but
we suggest that blood with visible clots should not be tested with
the Xpert platform.
Multiple studies from Africa with blood culture have demon-
strated that TB is a common cause of BSI (24), and our data add to
the existing evidence that it is an important cause of a high early
death rate (25). Previous studies have not provided sufficiently
timely data for clinical intervention, but the rapid diagnosis ofM.
tuberculosis bacteremia via the Xpert-MTB/RIF platform provides
the opportunity to target patients at high risk of death. There is
therefore an urgent need to investigate the conditions under
which empirical or early treatment for M. tuberculosis sepsis
should be commenced in order to prevent the high early death rate
TABLE 3 Comparison of clinical characteristics of patients in different diagnostic categoriesa
Diagnostic category or
parameter
No. (%) of
males
Mean age, yr
(SD)
Mean illness duration,
wk (SD)
Mean hemoglobin level,
g/dl (SD)
Median CD4 cell
count/l (IQR)b
Xpert blood positive 9 (90) 38.1 (1.5) 3 (1.0–4.0) 6.8 (0.7) 54 (48–60)
PTB and Xpert blood negative 22 (63) 35.3 (2) 4 (2.0–8.0) 9 (0.4) 89 (29–373)
Treated, unconfirmed TB 21 (78) 37.1 (1.6) 4 (2.0–8.0) 9.2 (0.5) 108 (36–351)
Not TB 17 (53) 38.2 (2) 2.5 (1.0–12.0) 10.4 (0.5) 152 (23–490)
P value 0.11 0.71 0.82 0.001 0.09
a Continuous parametric data (age, hemoglobin level, and duration of illness) were analyzed by ANOVA, continuous nonparametric data (CD4 cell count) were analyzed by
Kruskal-Wallis test, and categorical data (gender) were analyzed by chi2 test.
b IQR, interquartile range.
FIG 2 Kaplan-Meier survival plots by TB diagnostic group (Xpert MTB/RIF
blood assay positive, culture-confirmed TB/Xpert blood assay negative,
treated unconfirmed TB, and not TB).
TABLE 4 Univariate and multivariate analyses of risk factors for early
death (2 weeks)a
Risk factor
OR (95 % CI)
Univariate analysis Multivariate analysis
Xpert blood positivity 20.22 (3.66–111.78) 43.93 (2.92–661.55)
Low hemoglobin level 5.96 (1.34–26.58) 4.25 (0.51–35.68)
Low CD4 cell count 3.81 (0.83–17.51) 6.56 (0.36–120.20)
a Odds ratios per unit change in hemoglobin and CD4 count categories are shown.
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we have observed, starting with patients in regions with a high
HIV prevalence who present with severe sepsis.
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